| |
Figure 4. Mevinolin treatment and Dhcr7-knockdown cause comparable phenotypes. a-d', i-i rdquo : Untreated embryos. e-h', j-j rdquo : Embryos treated with 125 mu M Mevinolin. k-k rdquo : Embryo treated with 25 mu M AY9944. l-l rdquo : Embryo treated with 250 mu M AY9944. m-m rdquo : Embryo treated with a combination of 25 mu M AY9944 and 12.5 mu M Mevinolin. The embryos are all treated from stage 8. a, c, e, g: Anterior views (dorsal up). b', d', f', h': Frontal views (dorsal up). b, d, f, h, i, i', j, j', k, k', l, l', m, m': Lateral views (dorsal up), (i rdquo , j rdquo , k rdquo , l rdquo , m rdquo ) dorsal views. a-d', e-h': WMISH analysis of the expression of Xsix3 (a-b'; e-f') and Xrx1/Xkrox20/Xen2 (c-d'; g-h'). j-m rdquo : Head phenotype. e-h': Early Xsix3 (e) and Xrx1 (g) expression is not affected by Mevinolin treatment; however, their expression at tailbud stage (f-f', h-h') is severely reduced. j-j': At tadpole stage, the Mevinolin-treated embryo displays small eyes that are fused to the midline, with a failure of the optic cup to close properly. k-k rdquo : Treatment with 25 mu M AY9944 does not cause any obvious phenotype. l-l rdquo : AY9944 treatment at 250 mu M results in developmental delay, small head phenotype with a loss of cement gland (arrow in l), and bended tail. The eyes are small, shifted towards the midline, and display a colobama. m-m rdquo : Combination of 25 mu M AY9944 and a low concentration of Mevinolin results in the same phenotype as a high concentration of AY9944. |
